Conference Track

Management of Antiretroviral-Naive Patients

Source: CCO Independent Conference Coverage of the 2009 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Recent Exposure to Abacavir and Cumulative Exposure to Lopinavir/Ritonavir and (Fos)amprenavir Associated With Increased Risk for Myocardial Infarction Among HIV-Infected Patients in French Cohort
D:A:D Study: Increased Risk for MI Among HIV-Infected Patients With Exposure to Abacavir, Didanosine, Indinavir, or Lopinavir/Ritonavir
Short-term Antiretroviral Treatment During Primary HIV-1 Infection Prolongs Time to Initiation of Chronic Treatment
NA-ACCORD: Initiating Antiretroviral Therapy With CD4+ Cell Count > 500 cells/mm³ Significantly Lowers Predicted Risk of Mortality
Observational Analysis of Multiple Observational Cohorts Supports Initiating Antiretroviral Therapy at CD4+ Cell Count Thresholds of 350 cells/mm³
OCTANE: Rate of Virologic Failure or Death Higher With Nevirapine- vs Lopinavir/Ritonavir-Based Antiretroviral Regimens Among HIV-Infected Women With Previous Exposure to Single-Dose Nevirapine
Rate of Single-Drug Substitution Lower With Tenofovir vs Stavudine or Zidovudine-Based First-line Antiretroviral Regimens Among HIV-Infected Patients in Zambia
WIHS/MACS: Abacavir Use Not Independently Associated With Changes in hs-CRP, D-dimer, and IL-6 in Patients Receiving Antiretroviral Therapy
STARTMRK: Comparable Efficacy of First-line Raltegravir-Based Regimen Compared With Efavirenz-Based Regimen Across Subgroups
Virologic Benefit of Directly Observed Therapy Not Maintained Among HIV-Infected Drug Users Following Switch to Self-Administered Therapy
REACH Cohort: Antidepressant Use Associated With Lower HIV-1 RNA in Homeless Population, Mediated Through Improved Antiretroviral Adherence
Resistance Mutations Discordant Between Cerebrospinal Fluid and Blood in Majority of Patients
No Association Between Abacavir Use and Risk of Cardiovascular Events in Pooled Analysis of Randomized ACTG Trials
ACTG 5095: Increases in High-Sensitivity C-reactive Protein Observed in Women but Not Men and Not Associated With Abacavir Use
Tenofovir Use and PI Use Independently Associated With Proximal Renal Tubulopathy Among HIV-Infected Patients
HEAT: Little Difference in Renal Function Improvement With Abacavir/Lamivudine vs Tenofovir/Emtricitabine but More Renal Adverse Events With Tenofovir/Emtricitabine
No Sex-Associated Differences in Treatment Outcomes in Meta-analysis of FDA Database of Registrational Trials for Antiretroviral Drugs From 2000-2008

Expert Analysis

Management of Antiretroviral-Naive Patients

Faculty:

Joel E. Gallant, MD, MPH
W. David Hardy, MD
Kathleen E. Squires, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize new findings on the clinical impact of initiating antiretroviral therapy at higher CD4+ cell counts
Discuss recent data on the association between abacavir use and cardiovascular disease risk
Describe new results on proximal renal tubular dysfunction in patients receiving tenofovir-containing antiretroviral therapy
Articulate the latest data on key factors associated with patient adherence to antiretroviral therapy
Cite outcomes from recent studies investigating the efficacy of antiretroviral treatment strategies in resource-limited settings, including methods to prevent mother-to-child HIV-1 transmission

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: 03/26/09

Expiration Date: 03/25/10

Physicians: maximum of 1.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.9 Nursing contact hours

Pharmacists: 1.9 contact hours (0.19 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.